AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00473200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S-adenosylmethionine
Description: 1200 mg daily
Study NCT00473200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-adenosylmethionine
Description: 1200 mg daily
Study NCT06209827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for reducing benzodiazepines long-term use.
Description: Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor.
Study NCT01969955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
Study NCT02206035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
Study NCT00490815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.5 mg fluocinolone acetonide intravitreal insert
Study NCT00490815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.2 mg fluocinolone acetonide intravitreal insert
Study NCT01103661 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Numeris®-AF Guided Coagulation System with VisiTrax®
Description: Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
Study NCT05850637 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant ultra-hypofractionated radiotherapy
Description: adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
Study NCT02449733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom choices
Description: Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 30
Description: Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study NCT01482767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
Study NCT02449733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom-compatible lubricant choices
Description: Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Study NCT02449733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples HIV counseling and testing (CVCT)
Description: Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
Study NCT02449733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit.
Study NCT02449733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Testing
Description: Rapid HIV testing at multiple time points
Study NCT02449733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linkage to care
Description: Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
Study NCT02449733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP)
Description: Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
Study NCT02449733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-reduction counseling
Description: Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
Study NCT01395420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ104
Description: IV Infusion
Study NCT02723461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile Oxytocin
Description: Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Study NCT02074150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox subdermally
Description: Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Study NCT02649712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Self-expandable biliary nitinol alloys stent
Study NCT01659957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Couples Counseling
Study NCT01659957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-One Couples Counseling
Study NCT02462863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine and fish oil
Description: Dietary supplements
Study NCT02723461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Oxytocin
Description: Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
Study NCT00063076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targretin Gel 1%
Description: Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
Study NCT02206035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
Study NCT02206035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1.
Study NCT00918489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
Study NCT01866826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
Study NCT01866826 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subject will receive three capsules of placebo by mouth twice daily.
Study NCT02330406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagliptin
Description: Suiny 100 mg
Study NCT02330406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Januvia 50 mg Glactiv 50 mg
Study NCT00057642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Study NCT00057642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine Extended Release
Study NCT00717769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN13834
Description: Low dose, orally 3 times a day (tid) for 28 days of SUN13834
Study NCT00717769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally (tid) for 28 days of SUN13834
Study NCT02269462 — intervention group
Intervention type: DRUG
Intervention: Efavirenz
Description: 600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
Study NCT02269462 — intervention group
Intervention type: DRUG
Intervention: Nevirapine
Description: 200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
Study NCT01449578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral Tablet at varying doses
Study NCT01449578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Oral tablet at varying doses
Study NCT04556942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow Mediated Dilation (FMD) measurement
Description: FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or > 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
Study NCT04556942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Flow Mediated Dilation (FMD) measurement
Description: FMD measurements will be performed by ultrasound using longitudinal images of the brachial artery using a high-frequency (10.0-MHz) ultrasound scanning probe (VividTM E9 with XDeclearTM; GE Healthcare, Chicago, Illinois, USA) proximal to the antecubital fossa. Two-dimensional images, acquired with electrocardiogram gating, will be obtained at baseline with Doppler ultrasound imaging to assess arterial diameter and flow velocity. Reactive hyperemia will then be induced by inflation of a pneumatic tourniquet around the forearm to at least 200 mm Hg (or > 50mmHg above systolic pressure) for 5 minutes. Post-deflation diameter and flow velocity will be monitored continuously from deflation for 210 seconds. To assess endothelial-independent vasodilation maximal brachial artery diameter will be measured continuously for 3 minutes after a single sublingual dose of nitroglycerin (NTG, 0.4 mg).
Study NCT04556942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure, pulse and blood oxygen saturation measurement
Description: Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient.
Study NCT04556942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure, pulse and blood oxygen saturation measurement
Description: Blood pressure measurement will be done with a pneumatic tourniquet on the upper arm, after at least 10 minutes rest of the patient.~Pulse measurement and oxygen saturation measurement will be done using a finger pulseoximeter, after at least 10 minutes rest of the patient.
Study NCT04556942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ST George Respiratory Questionnaire
Description: The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
Study NCT00835302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervicothoracic manipulation
Description: Thrust and non-thrust manipulation to the cervical and thoracic spine
Study NCT04625439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personality Feedback Self-Management Intervention
Description: The intervention is a personality feedback report that will tell participants whether they scored low (bottom third), average (middle third), or high (top third) on each of the five factor personality characteristics based on gender-matched norms. In addition to a description of general tendencies based on their level of each personality trait, the feedback will include information about how scoring in a given category may relate to an individual's cancer self-management or healthcare decision making. The feedback for each personality trait will include recommendations for how to improve key outcomes.
Study NCT01342588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric pulse train stimulation
Description: Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
Study NCT04556942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ST George Respiratory Questionnaire
Description: The is a validated and standardized Questionnaire designed to measure health impairment in COPD patients
Study NCT04556942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity level (PAL) measurement
Description: PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
Study NCT04289961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Portal vein sampling
Description: During Endoscopic UltraSound guided-Fine Needle Aspitation (EUS-FNA) a curvilinear echoendoscope is advanced to the distal stomach or duodenal bulb to provide a window of access to a branch of the PV. After verifying venous flow by Doppler signal, a 19-gauge EUS-FNA needle is advanced transhepatically into the portal vein branch. With the needle in the portal vein, the stylet is removed and negative-pressure suction is applied to aspirate blood. A transhepatic approach for portal vein branch access is an absolute requirement of this technique in order to minimize the risk of bleeding. The puncture site is monitored under EUS for complications.
Study NCT04556942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical activity level (PAL) measurement
Description: PAL will be assessed by the number of steps and kilometers per day using a triaxial accelerometer of a multisensory activity monitor (Fitbit Alta HR; Fitbit Inc., San Francisco, CA, USA). The device is worn like a watch on the wrist. The device is worn always, except while showering or swimming.
Study NCT04556942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Withdrawal of a blood sample
Description: 5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
Study NCT04556942 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Withdrawal of a blood sample
Description: 5ml of blood will be withdrawn and preserved after centrifugation at -50 degrees celsius for later analysis at a yet unknown time
Study NCT04556942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Bronchoscopic Lung Volume Reduction
Description: Bronchoscopic Lung Volume Reduction by using endobronchial valve placement Within 2 weeks after T0
Study NCT01302028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP1941
Description: Oral
Study NCT01302028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study NCT01080846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg of sublingual misoprostol
Study NCT02994875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
Study NCT02994875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT00413790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin tablets 15 mg once daily
Study NCT00413790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine extended release (ER) 4 mg once daily
Study NCT00413790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study NCT00697372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting stent
Description: Implantation of Sirolimus eluting stent
Study NCT00697372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: Implantation of Everolimus eluting stent
Study NCT01877213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching with coordinate care
Description: The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
Study NCT01382238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg tablet
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
Study NCT01382238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg oral granules
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
Study NCT01519856 — intervention group
Intervention type: DRUG
Intervention: piribedil (Clarium)
Description: oral tablets, 50 mg
Study NCT01737567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Narrow Band Imaging.
Description: Using Bright Narrow Band Imaging to detect colonic adenomas.
Study NCT01737567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Light Endoscopy
Description: Use of White Light Endoscopy to detect colonic adenomas.
Study NCT01865825 — intervention group
Intervention type: RADIATION
Intervention: Esophageal Barium Xray
Description: •Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day.